"Genes, erbB-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The erbB-2 gene is a proto-oncogene that codes for the erbB-2 receptor (RECEPTOR, ERBB-2), a protein with structural features similar to the epidermal growth factor receptor. Its name originates from the viral oncogene homolog (v-erbB) which is a truncated form of the chicken erbB gene found in the avian erythroblastosis virus. Overexpression and amplification of the gene is associated with a significant number of adenocarcinomas. The human c-erbB-2 gene is located at 17q21.2.
| Descriptor ID |
D018734
|
| MeSH Number(s) |
G05.360.340.024.340.375.500.791.295.305
|
| Concept/Terms |
Genes, erbB-2- Genes, erbB-2
- c-erbB-2 Genes
- c erbB 2 Genes
- c-erbB-2 Gene
- Genes, erbb2
- Gene, erbb2
- erbb2 Gene
- erbb2 Genes
- Genes, HER-2
- HER-2 Gene
- HER-2 Genes
- Genes, neu
- neu Gene
- neu Genes
- Genes, HER2
- Gene, HER2
- HER2 Gene
- HER2 Genes
- erbB-2 Genes
- erbB 2 Genes
- erbB-2 Gene
- c-erbB-2 Proto-Oncogenes
- c erbB 2 Proto Oncogenes
- c-erbB-2 Proto-Oncogene
|
Below are MeSH descriptors whose meaning is more general than "Genes, erbB-2".
Below are MeSH descriptors whose meaning is more specific than "Genes, erbB-2".
This graph shows the total number of publications written about "Genes, erbB-2" by people in this website by year, and whether "Genes, erbB-2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 2000 | 1 | 1 | 2 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 0 | 3 | 3 |
| 2006 | 0 | 1 | 1 |
| 2007 | 2 | 0 | 2 |
| 2009 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Genes, erbB-2" by people in Profiles.
-
Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models. Biomed Pharmacother. 2022 Mar; 147:112662.
-
Multi-omics colocalization with genome-wide association studies reveals a context-specific genetic mechanism at a childhood onset asthma risk locus. Genome Med. 2021 10 10; 13(1):157.
-
ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 05; 12(5):872-877.
-
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011 Dec 20; 29(36):4803-10.
-
Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol. 2009 Sep 20; 27(27):4515-21.
-
Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing. Arch Pathol Lab Med. 2008 Jun; 132(6):1008-15.
-
HER2-positive early breast cancer and trastuzumab: a surgeon's perspective. Ann Surg Oncol. 2008 Jun; 15(6):1677-88.
-
An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008 Jan; 108(1):3-9.
-
Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions. Rev Recent Clin Trials. 2007 May; 2(2):111-6.
-
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol. 2006 Sep 10; 24(26):4324-32.